Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 989

Sort by

Sort Order Select

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

Blood (2021) 137 (19): 2646–2656.

https://doi.org/10.1182/blood.2020008825

Published: 2021

Includes: Supplemental data

Journal Articles

EBV + diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

Lénaïg Mescam, Vincent Camus, Jean-Marc Schiano, José Adélaïde, Jean-Michel Picquenot, Arnaud Guille, Marie Bannier, Philippe Ruminy, Pierre-Julien Viailly, Fabrice Jardin, Reda Bouabdallah, Isabelle Brenot-Rossi, Elodie Bohers, Cyrielle Robe, Camille Laurent, Daniel Birnbaum, Andrew Wotherspoon, Philippe Gaulard, Luc Xerri

Blood (2020) 135 (22): 2004–2009.

https://doi.org/10.1182/blood.2019003408

Published: 2020

Includes: Supplemental data

Journal Articles

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Koen Debackere, Jo-Anne van der Krogt, Thomas Tousseyn, Julio Antonio Finalet Ferreiro, Katrien Van Roosbroeck, Lukas Marcelis, Carlos Graux, Daan Dierickx, Geneviève Ameye, Peter Vandenberghe, Lucienne Michaux, Jan Cools, Iwona Wlodarska

Blood (2020) 135 (8): 584–588.

https://doi.org/10.1182/blood.2019002401

Published: 2020

Includes: Supplemental data

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

Journal Articles

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Joseph Maakaron, MD, Qiuhong Zhao, MS, Marcin Puto, PharmD, Quinn Verfurth, Sam Penza, MD, Jonathan E Brammer, MD, Yvonne A. Efebera, MD MPH, Ashley E. Rosko, MD, Ayman Saad, MD, Samantha Jaglowski, MDMPH, Basem M. William, MRCP,MD

Blood (2019) 134 (Supplement_1): 2024.

https://doi.org/10.1182/blood-2019-126994

Published: 2019

Journal Articles

Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Experience

Juan F Garza, MD, Michelle Janania Martinez, MD, Prathibha Surapaneni, MD, Tyler W Snedden, MD, Snegha Ananth, MBBS, David J Gregorio, DO, Sushanth Kakarla, MD, Jeremy Rawlings, MD, Joel E Michalek, PhD, Qianqian Liu, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2141.

https://doi.org/10.1182/blood-2019-129085

Published: 2019

Journal Articles

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Nicolas Martinez-Calle, MD MSc, Amy A. Kirkwood, MSc, Maxine Lamb, PhD, Alexandra Smith, PhD, Kate Manos, Caroline Shrubsole, MD, Nicola Gray, Sapna Ladani, MRCP, Katharine Louise Lewis, BMBS, FRCPath, MRCPath, Mark Bishton, Matthew J Ahearne, MDMBBS, Eliza A Hawkes, Wendy Osborne, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Cathy Burton, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 2849.

https://doi.org/10.1182/blood-2019-122083

Published: 2019

Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD

Blood (2019) 134 (Supplement_1): 2853.

https://doi.org/10.1182/blood-2019-123801

Published: 2019

Journal Articles

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Shoko Oshima, MD, Akihito Shinohara, MD, Hideki Ishida, MD PhD, Miki Umeda, MD, Satoko Osanai, MD, Satoru Itoi, MD, Michiko Ryuzaki, MD, Yuki Izuka, MD, Aya Watanabe, MD, Norina Tanaka, MD PhD, Midori Ishiyama, MD PhD, Hiroshi Kazama, MD PhD, Kentaro Yoshinaga, MD PhD, Shotaro Hagiwara, MD PhD, Masayuki Shiseki, MD PhD, Junji Tanaka, MD PhD

Blood (2019) 134 (Supplement_1): 2910.

https://doi.org/10.1182/blood-2019-125601

Published: 2019

Journal Articles

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Joanna M Rhodes, MD, Suchitra Sundaram, MD, Adam Zayac, MD, Adam J Olszewski, MD, Paolo Caimi, MD, Zachary Braunstein, MD, Jonathan E Brammer, MD, Waqas Jehangir, MD, Elvira Umyarova, MD, Sheenu Sheela, MD, Nilanjan Ghosh, MD PhD, Sunita Dwivedy Nasta, MD, Stefan K. Barta, MD MRCP, MS

Blood (2019) 134 (Supplement_1): 2854.

https://doi.org/10.1182/blood-2019-124447

Published: 2019

Journal Articles

Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples

Jonathan Rink, PhD, Adam Yuh Lin, MD PhD, Shuo Yang, PhD, Amir Behdad, MD, Reem Karmali, MD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 2857.

https://doi.org/10.1182/blood-2019-127805

Published: 2019

Journal Articles

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Timothy J Voorhees, MD, Natalie S Grover, MD, Jonathan Galeotti, MD MS, Nathan D Montgomery, MD, Dominic T. Moore, MPH, MS, Anne Beaven, MD, Christopher Dittus, DO

Blood (2019) 134 (Supplement_1): 2915.

https://doi.org/10.1182/blood-2019-126228

Published: 2019

Journal Articles

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Swaminathan P. Iyer, MD, Brad M. Haverkos, MDMPH,MS, Jasmine Zain, MD, Radhakrishnan Ramchandren, MD, Mary Jo Lechowicz, MD, Sumana Devata, MD, Neil Korman, MD, Lauren C. Pinter-Brown, MD, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD, Auris Huen, MD

Blood (2019) 134 (Supplement_1): 2831.

https://doi.org/10.1182/blood-2019-123954

Published: 2019

Journal Articles

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

Shuo Liu, Zhengming Jin, Depei Wu, MD PhD, Haiwen Huang, MD PhD

Blood (2019) 134 (Supplement_1): 3315.

https://doi.org/10.1182/blood-2019-125666

Published: 2019

Journal Articles

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Hongyu Zhang, MD PhD, Jia Feng, MD PhD, Wenli Zhang, MD, Qi Chen, PhD, Yuanzhen Cao, Kevin Pinz, Fang Liu, MD PhD, Yu Ma, Masayuki Wada, PhD, Yupo Ma, MD PhD

Blood (2019) 134 (Supplement_1): 2881.

https://doi.org/10.1182/blood-2019-122789

Published: 2019

Journal Articles

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Teresa Poggio, Linda Graessel, Stefanie Kreutmair, Cornelius Miething, Dietmar Pfeifer, Geoffroy Andrieux, Melanie Boerries, Marie Follo, Suzanne Turner, Robert Zeiser, MD, Justus Duyster, MD, Anna Lena Illert

Blood (2019) 134 (Supplement_1): 2542.

https://doi.org/10.1182/blood-2019-125589

Published: 2019

Journal Articles

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Anthony K. N. Chan, PhD, Christopher D. Delaney, Lu Yang, PhD, Wen-Han Chang, PhD, Kazuya Miyashita, PhD, Qiao Liu, MD, Sheela Pangeni Pokharel, MSc, Scott A. Armstrong, MD PhD, Chun-Wei David Chen, PhD

Blood (2019) 134 (Supplement_1): 530.

https://doi.org/10.1182/blood-2019-131467

Published: 2019

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

NARROW

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL

EBV + diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant–related lymphomas

FER and FES tyrosine kinase fusions in follicular T-cell lymphoma

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL)

Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Experience

An International Multicentre Study of Consecutively Diagnosed Patients with ALCL: Outcomes Following First-Line Therapy in Routine Clinical Practice

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Clinical Features of Post-Transplant Lymphoproliferative Disease Are Different between Kidney-Transplant Recipients from a Cadaveric Donor and Those from a Living Donor

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)

Bio-Inspired Functional Lipoprotein-like Nanoparticles (Flip-NPs) Cause Cholesterol Starvation and Ferroptosis in B-Cell Lymphomas: Studies in Cell Lines, Xenograft Models and Primary Patient Samples

High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant - a Single Center Experience

Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma

Outcome of Autologous Hematopoietic Cell Transplantation in First Complete Remission(CR1) in Patients with Peripheral T-Cell Lymphomas(PTCLs)

First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma

Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only